Literature DB >> 15578923

Bacteria and bacterial toxins as therapeutic agents for solid tumors.

P Michl1, T M Gress.   

Abstract

Patients with advanced solid tumors frequently relapse and succumb to their metastatic disease after developing resistance to conventional treatment modalities such as chemotherapy and radiotherapy. In these patients, novel strategies of targeting widespread tumors are urgently needed. The increasing knowledge of the underlying pathogenetic mechanisms has led to the identification of numerous molecules that are overexpressed in various tumors and accumulate at the cell surface. The use of genetically modified bacteria and their toxins targeting these surface molecules has emerged as a promising new treatment strategy in refractory cancers. This review focuses on bacterial toxins such as Diphtheria toxin (DT), Pseudomonas exotoxin A (PE) and Clostridium perfringens enterotoxin (CPE). In addition, the use of anaerobic bacteria such as Clostridium, Salmonella and Bifidobacterium spp. as drug-delivery systems targeting hypoxic tumor areas will be discussed as a new therapeutic modality of advanced solid tumors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15578923     DOI: 10.2174/1568009043332727

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  12 in total

1.  Targeted tumor gene therapy based on loss of IGF2 imprinting.

Authors:  Yuqin Pan; Bangshun He; Tao Li; Chan Zhu; Lirong Zhang; Bo Wang; Yongfei Xu; Lili Qu; Andrew R Hoffman; Shukui Wang; Jifan Hu
Journal:  Cancer Biol Ther       Date:  2010-08-21       Impact factor: 4.742

Review 2.  Microbial-based therapy of cancer: current progress and future prospects.

Authors:  Nuno Bernardes; Raquel Seruca; Ananda M Chakrabarty; Arsenio M Fialho
Journal:  Bioeng Bugs       Date:  2009-12-02

3.  A Brief Introduction to Current Cancer Gene Therapy.

Authors:  Dennis Kobelt; Jessica Pahle; Wolfgang Walther
Journal:  Methods Mol Biol       Date:  2022

4.  Prospects for the use of artificial chromosomes and minichromosome-like episomes in gene therapy.

Authors:  Sara Pérez-Luz; Javier Díaz-Nido
Journal:  J Biomed Biotechnol       Date:  2010-08-24

5.  Clinicopathological significance of claudin 4 expression in gastric carcinoma: a systematic review and meta-analysis.

Authors:  Xiaowan Chen; Junhua Zhao; Ailin Li; Peng Gao; Jingxu Sun; Yongxi Song; Jingjing Liu; Ping Chen; Zhenning Wang
Journal:  Onco Targets Ther       Date:  2016-05-27       Impact factor: 4.147

Review 6.  Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges.

Authors:  Shaowei Zhu; Yuanyi Liu; Paul C Wang; Xinbin Gu; Liang Shan
Journal:  Biomed Res Int       Date:  2017-06-29       Impact factor: 3.411

7.  A novel Bifidobacterium infantis-mediated TK/GCV suicide gene therapy system exhibits antitumor activity in a rat model of bladder cancer.

Authors:  Wei Tang; Yunfeng He; Shengcai Zhou; Yongping Ma; Geli Liu
Journal:  J Exp Clin Cancer Res       Date:  2009-12-16

8.  Challenging the roles of CD44 and lipolysis stimulated lipoprotein receptor in conveying Clostridium perfringens iota toxin cytotoxicity in breast cancer.

Authors:  Katerina D Fagan-Solis; Denise K Reaves; M Cristina Rangel; Michel R Popoff; Bradley G Stiles; Jodie M Fleming
Journal:  Mol Cancer       Date:  2014-07-02       Impact factor: 27.401

9.  Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells.

Authors:  Nathan De Beule; Eline Menu; Mathieu J M Bertrand; Mérédis Favreau; Elke De Bruyne; Ken Maes; Kim De Veirman; Magdalena Radwanska; Afshin Samali; Stefan Magez; Karin Vanderkerken; Carl De Trez
Journal:  Oncotarget       Date:  2017-05-24

10.  Recombinant production and affinity purification of the FraC pore forming toxin using hexa-His tag and pET expression cassette.

Authors:  Mehdi Imani; Hossein Zarei Jaliani; Mohammad Hassan Kheirandish; Mahnaz Azadpour
Journal:  Iran J Basic Med Sci       Date:  2017-04       Impact factor: 2.699

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.